Pityriasis rosea during etanercept therapy

Multiple bioengineered agents has been recently developed to attack other parts of the immune/inflammatory system, achieving therapeutic implications for dermatologie diseases. On the other side, each new therapy has the potential for adverse cutaneous reactions. We present herein the first two cases of Gibert's pityriasis rosea occurring during etanercept therapy and discuss possible links between this common, etiologically still unexplained exanthema and anti-tumor necrosis factor-α drugs.